ArticlemSphere2019
A Live
Article in mSphere, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 21 citations in OpenAlex.
- Innovations in cancer treatment as novel potential and the myth of personalized vaccines, immunotherapy, CRISPR/Cas9, and bacteriotherapy as promising therapeutic strategies.Discover oncology · 2025Review
- Genetic engineering ofEcoSal Plus · 2024Review
- Advancing vaccine technology through the manipulation of pathogenic and commensal bacteria.Materials today. Bio · 2024Review
- Recruitment of heterologous substrates by bacterial secretion systems for transkingdom translocation.Frontiers in cellular and infection microbiology · 2023Review
- Review
- An Engineered Outer Membrane-DefectiveJournal of microbiology and biotechnology · 2022Article
- Vaccination to PreventFrontiers in microbiology · 2022Article
- Advances in the development of Salmonella-based vaccine strategies for protection against Salmonellosis in humans.Journal of applied microbiology · 2021Review
- Metallacarborane Derivatives Effective againstInternational journal of molecular sciences · 2021Article
- Secretory System Components as Potential Prophylactic Targets for Bacterial Pathogens.Biomolecules · 2021Review
- UnderstandingCells · 2020Review
- Delivery of Heterologous Proteins, Enzymes, and Antigens via the Bacterial Type III Secretion System.Microorganisms · 2020Review
- Bacterial injection machines: Evolutionary diverse but functionally convergent.Cellular microbiology · 2020Article
- Protective Efficacy of the OprF/OprI/PcrV Recombinant Chimeric Protein AgainstInfection and drug resistance · 2020Article
- Emerging therapies against infections withF1000Research · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.